Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses
Journal of Virology · 2026
DOI: 10.1128/jvi.00749-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, 2026. Verfasst von Sanjeev Kumar und 24 weiteren Autor:innen. Beteiligte Einrichtung: Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory Univ…. Hauptthemen laut MEDLINE: SARS-CoV-2, Antibodies, Viral, COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIBIB NIH HHS, Emory University.
Abstract (Originalsprache)
The emergence of the SARS-CoV-2 Omicron BA.2.86 subvariant, a lineage derived from the BA.2 strain, led to the 2024–2025 COVID-19 vaccine update to include KP.2 or related JN.1-lineage spike antigens. We evaluated the magnitude, breadth, and durability of humoral immune responses following a single KP.2 vaccine dose in a longitudinal cohort of 21 individuals up to 6 months. KP.2 vaccination increased spike-specific binding and neutralizing antibodies against the ancestral WA.1 strain, as well as against the BA.5, XBB.1.5, and KP.2 variants. Power-law modeling estimated half-lives for WA.1- and KP.2-specific IgG responses at 770 and 248 days, respectively. Additionally, the KP.2 dose increased IgG1 and IgG4 subclasses more than IgG2 and IgG3 responses to both spike proteins. Serum-depletion experiments using WA.1 or KP.2 proteins demonstrated that most vaccine-elicited antibodies were cross-reactive. Consequently, KP.2 vaccine-induced antibodies retained broad neutralizing activity against recently circulating Omicron subvariants (BA.2.86, KP.3.1.1, XEC, LP.8.1, LF.7, XFG.3.12, PQ.1, BA.3.2.1, and RE.2). Using a live virus neutralization assay, XFG.3.12 showed the greatest reduction in neutralizing titers relative to KP.2 (4.2-fold). In a small subset, an LP.8.1 vaccine dose increased neutralizing activity against the matched variant while maintaining WA.1 and KP.2 cross-reactivity, but only modestly increased antibodies to divergent variants BA.3.2.1 and RE.2. Ultimately, these data indicate the KP.2 mRNA vaccine generates durable, cross-reactive responses against current Omicron subvariants. However, ongoing spike evolution impacts the neutralization of emerging lineages, highlighting the need for continued viral monitoring and timely vaccine updates. IMPORTANCE SARS-CoV-2 continues to evolve, raising ongoing concerns about how well updated vaccines protect against emerging variants. This study evaluates antibody responses after a KP.2 spike mRNA vaccine dose. It shows that a single dose induces durable and broadly cross-reactive immunity against both earlier strains and recently circulating Omicron subvariants. Despite this breadth, reduced neutralizing activity against certain emerging variants indicates that ongoing antigenic changes can impact vaccine-induced antibody effectiveness. These findings provide insight into how current vaccines perform over time and highlight the need to track viral evolution and update vaccine antigens to maintain broad protection against severe disease, hospitalization, and death.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Childhood Infections and Vaccines, Children's Healthcare of Atlanta, Division of Infectious Diseases, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
- Emory Vaccine Center, Emory University, Atlanta, Georgia, USA.
- Emory National Biomedical Research Center, Atlanta, Georgia, USA.
- Department of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA.
- Hope Clinic of Emory Vaccine Center, Emory University, Decatur, Georgia, USA.
- Coronavirus and Other Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
ORCID-Profile: Sanjeev Kumar, Peter Cook, Clint Paden, Nadine Rouphael, Eric A Ortlund, Vineet D Menachery, Jens Wrammert, Mehul S Suthar
Förderung
- NIH HHS
- NIBIB NIH HHS
- Emory University
- NIAID NIH HHS
- National Institutes of Health
Zitieren
APA
Kumar, S., Lai, L., Ellis, M. L., Patel, A., Joshi, D., Vander Velden, J. W., Faraj, J. Z. A., Wimalasena, S. T., Pallavi, R. R., Iriss, J., Bechnak, K., Cook, P., Gardner, M. E., Hicks, H. N., Tamin, A., Paden, C., Harcourt, J. L., Edupuganti, S., Rouphael, N., …, & Suthar, M. S. (2026). Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses. Journal of Virology. https://doi.org/10.1128/jvi.00749-26
Vancouver
Kumar S, Lai L, Ellis ML, Patel A, Joshi D, Vander Velden JW, et al. Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses. Journal of Virology. 2026. doi:10.1128/jvi.00749-26
BibTeX
@article{Kumar2026,
author = {Kumar, Sanjeev and Lai, Lilin and Ellis, Madison L and Patel, Anamika and Joshi, Devyani and Vander Velden, Jacob W and Faraj, Jana Ziad Abu and Wimalasena, Sonia T and Pallavi, Ramitha R and Iriss, Jad and Bechnak, Kareem and Cook, Peter and Gardner, Meredith E and Hicks, Heather N and Tamin, Azaibi and Paden, Clint and Harcourt, Jennifer L and Edupuganti, Sri and Rouphael, Nadine and Ortlund, Eric A and Moreno, Alberto and Menachery, Vineet D and Zarnitsyna, Veronika I and Wrammert, Jens and Suthar, Mehul S},
title = {Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses},
journal = {Journal of Virology},
year = {2026},
doi = {10.1128/jvi.00749-26}
}
EUVIMED